Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung also compares the differing challenges of the oncology and neuroscience markets and outlines the unique Eisai company culture.
We have learned that to perform well in the US, we need to have a consistently robust pipeline instead of relying on just one or two blockbusters
Reflecting on a transformational decade at the helm of the Drug Information Association (DIA), Barbara Lopez Kunz highlights some of the key achievements and most significant trends that have emerged…
Dan Leonard, President and CEO of the Association for Accessible Medicines (AAM) and Erik C. Komendant, the organisation’s Senior Vice President of Government Affairs, spoke to us about drug pricing…
Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of…
Nominated by President Joe Biden, the National Institutes of Health’s (NIH) new director Monica M. Bertagnolli took the reins of the world’s largest public funder of biomedical research earlier this…
Francesco Lanucara of PharmaLex, writing in the November 2023 edition of the DIA’s Global Forum magazine takes a look at how new guidance from the US FDA aims to tackle…
The speed with which Pfizer-BioNTech and Moderna’s COVID-19 vaccines were brought forward may have made the mRNA technology behind them appear novel. In fact, the pioneers whose discoveries enabled the…
See our Cookie Privacy Policy Here